Peter C. Richardson

Insider Reports History

Location
Valencia, CA
Signature
/s/ Mark Tyndall, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Peter C. Richardson:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Mallinckrodt plc EVP & Chief Scientific Officer Restricted Stock Units 27.4K Jul 31, 2025 Direct
Mallinckrodt plc EVP & Chief Scientific Officer Ordinary Shares 3.42K $37.50 Jan 1, 2025 Direct
ANTARES PHARMA, INC. EVP, Research and Development and Chief Medical Officer Common Stock 0 $5.60 May 24, 2022 Direct
ANTARES PHARMA, INC. EVP, Research and Development and Chief Medical Officer Stock Option (right to buy) 0 May 24, 2022 Direct

Insider Reports Filed by Peter C. Richardson

Symbol Company Period Transactions Value $ Form Type Date Filed Role
Mallinckrodt plc Jul 31, 2025 1 $0 4 Aug 4, 2025 EVP & Chief Scientific Officer
NONE Mallinckrodt plc Jan 1, 2025 2 $0 4 Jan 2, 2025 EVP & Chief Scientific Officer
NONE Mallinckrodt plc Feb 2, 2024 1 $0 4 Feb 6, 2024 EVP & Chief Scientific Officer
MNKTQ Mallinckrodt plc Nov 14, 2023 1 $0 4 Nov 16, 2023 EVP & Chief Scientific Officer
MNK Mallinckrodt plc Jun 30, 2023 1 $0 4 Jul 5, 2023 EVP & Chief Scientific Officer
MNK Mallinckrodt plc Apr 3, 2023 1 $0 4 Apr 5, 2023 EVP & Chief Scientific Officer
MNK Mallinckrodt plc Feb 2, 2023 1 $0 4 Feb 3, 2023 EVP & Chief Scientific Officer
MNK Mallinckrodt plc Jan 12, 2023 0 $0 3 Jan 20, 2023 EVP & Chief Scientific Officer
ATRS ANTARES PHARMA, INC. May 24, 2022 4 -$283K 4 May 26, 2022 EVP, Research and Development and Chief Medical Officer
ATRS ANTARES PHARMA, INC. Jun 10, 2021 2 $160K 4 Jun 14, 2021 EVP, R&D Chief Medical Officer